These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21520208)

  • 1. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies.
    Goralczyk AD; Hauke N; Bari N; Tsui TY; Lorf T; Obed A
    Hepatology; 2011 Aug; 54(2):541-54. PubMed ID: 21520208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.
    Crins ND; Röver C; Goralczyk AD; Friede T
    Pediatr Transplant; 2014 Dec; 18(8):839-50. PubMed ID: 25283839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials.
    Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    J Heart Lung Transplant; 2008 Aug; 27(8):835-42. PubMed ID: 18656795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
    Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
    Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.
    Webster AC; Playford EG; Higgins G; Chapman JR; Craig JC
    Transplantation; 2004 Jan; 77(2):166-76. PubMed ID: 14742976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis.
    Ali H; Soliman KM; Shaheen I; Kim JJ; Kossi ME; Sharma A; Pararajasingam R; Halawa A
    Int Urol Nephrol; 2020 Apr; 52(4):791-802. PubMed ID: 32170593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients.
    Lim W; Chadban S; Campbell S; Dent H; Russ G; McDonald S
    Transpl Int; 2010 Dec; 23(12):1207-15. PubMed ID: 20536789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression.
    Cillo U; Bechstein WO; Berlakovich G; Dutkowski P; Lehner F; Nadalin S; Saliba F; Schlitt HJ; Pratschke J
    Transplant Rev (Orlando); 2018 Jul; 32(3):142-150. PubMed ID: 29709248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
    Peng W; Liu G; Xie W; Huang H; Wu J; Shou Z; Chen J
    Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
    Tan J; Wu W; Xu X; Liao L; Zheng F; Messinger S; Sun X; Chen J; Yang S; Cai J; Gao X; Pileggi A; Ricordi C
    JAMA; 2012 Mar; 307(11):1169-77. PubMed ID: 22436957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: A retrospective cohort study.
    Xue M; Lv C; Chen X; Huang X; Sun Q; Wang T; Liang J; Zhang Y; He S; Gao J; Zhou J; Yu M; Fan J; Gao X
    J Diabetes; 2016 Jul; 8(4):579-87. PubMed ID: 26588180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
    Nashan B
    BioDrugs; 2005; 19(1):39-46. PubMed ID: 15691216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation.
    Ahsan N
    Minerva Urol Nefrol; 2003 Mar; 55(1):67-79. PubMed ID: 12773968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.
    Vincenti F; de Andrés A; Becker T; Choukroun G; Cole E; González-Posada JM; Kumar MA; Moore R; Nadalin S; Nashan B; Rostaing L; Saito K; Yoshimura N
    Transpl Int; 2006 Jun; 19(6):446-57. PubMed ID: 16771865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid avoidance or withdrawal for kidney transplant recipients.
    Pascual J; Zamora J; Galeano C; Royuela A; Quereda C
    Cochrane Database Syst Rev; 2009 Jan; (1):CD005632. PubMed ID: 19160257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
    Nashan B
    Clin Transplant; 2013; 27 Suppl 25():16-29. PubMed ID: 23909498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.